Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) announced the acceptance of its abstract submission by the American Society of Clinical Oncology (ASCO) for its 2025 Annual Meeting. The abstract focuses on concordance analysis between blood and marrow samples using the TeloView® Minimal Residual Disease (MRD) methodology.
The company's ongoing MRD clinical trials with McGill University/Jewish General Hospital aim to develop two prognostic tests: 1) identifying and quantifying MRD cells in patient's blood post marrow transplantation, and 2) profiling isolated circulating MRD cells using TeloView® technology to assess disease aggressiveness. Both tests are designed as liquid biopsy-based solutions.
This development follows the FDA's Oncologic Drugs Advisory Committee's unanimous vote in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) ha annunciato l'accettazione della sua presentazione astratta da parte della American Society of Clinical Oncology (ASCO) per il suo Annual Meeting del 2025. L'abstract si concentra sull'analisi di concordanza tra campioni di sangue e midollo osseo utilizzando la metodologia TeloView® Minimal Residual Disease (MRD).
Le attuali sperimentazioni cliniche dell'azienda sul MRD con l'Università McGill/Ospedale Generale Ebraico mirano a sviluppare due test prognostici: 1) identificare e quantificare le cellule MRD nel sangue del paziente dopo il trapianto di midollo, e 2) profilare le cellule MRD circolanti isolate utilizzando la tecnologia TeloView® per valutare l'aggressività della malattia. Entrambi i test sono progettati come soluzioni basate su biopsie liquide.
Questo sviluppo segue il voto unanime del Comitato Consultivo sui Farmaci Oncologici della FDA nell'aprile 2024, che ha accettato il MRD come endpoint clinico per l'approvazione accelerata di nuove terapie per il mieloma multiplo.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) anunció la aceptación de su presentación de resumen por parte de la American Society of Clinical Oncology (ASCO) para su Reunión Anual de 2025. El resumen se centra en el análisis de concordancia entre muestras de sangre y médula ósea utilizando la metodología TeloView® Minimal Residual Disease (MRD).
Los ensayos clínicos en curso de la empresa sobre MRD con la Universidad McGill/Hospital General Judío tienen como objetivo desarrollar dos pruebas pronósticas: 1) identificar y cuantificar las células MRD en la sangre del paciente después del trasplante de médula, y 2) perfilar las células MRD circulantes aisladas utilizando la tecnología TeloView® para evaluar la agresividad de la enfermedad. Ambas pruebas están diseñadas como soluciones basadas en biopsia líquida.
Este desarrollo sigue la votación unánime del Comité Asesor de Medicamentos Oncológicos de la FDA en abril de 2024 para aceptar el MRD como un punto final clínico para la aprobación acelerada de nuevas terapias para el mieloma múltiple.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF)는 American Society of Clinical Oncology (ASCO)가 2025년 연례 회의에 대한 초록 제출을 수락했다고 발표했습니다. 이 초록은 TeloView® Minimal Residual Disease (MRD) 방법론을 사용하여 혈액과 골수 샘플 간의 일치성 분석에 중점을 둡니다.
회사의 McGill 대학교/유대인 일반 병원과 함께 진행 중인 MRD 임상 시험은 두 가지 예후 테스트를 개발하는 것을 목표로 합니다: 1) 골수 이식 후 환자의 혈액에서 MRD 세포를 식별하고 정량화하는 것, 2) TeloView® 기술을 사용하여 분리된 순환 MRD 세포를 프로파일링하여 질병의 공격성을 평가하는 것입니다. 두 테스트 모두 액체 생검 기반 솔루션으로 설계되었습니다.
이 개발은 2024년 4월 FDA의 종양학 약물 자문 위원회가 새로운 다발성 골수종 치료제의 가속 승인을 위한 임상 최종점으로 MRD를 수락하기 위한 만장일치 투표를 따른 것입니다.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) a annoncé l'acceptation de sa soumission d'abstract par la American Society of Clinical Oncology (ASCO) pour sa réunion annuelle de 2025. L'abstract se concentre sur l'analyse de concordance entre des échantillons de sang et de moelle osseuse utilisant la méthodologie TeloView® Minimal Residual Disease (MRD).
Les essais cliniques en cours de l'entreprise sur le MRD avec l'Université McGill/Hôpital Général Juif visent à développer deux tests pronostiques : 1) identifier et quantifier les cellules MRD dans le sang du patient après une transplantation de moelle, et 2) profiler les cellules MRD circulantes isolées utilisant la technologie TeloView® pour évaluer l'agressivité de la maladie. Les deux tests sont conçus comme des solutions basées sur des biopsies liquides.
Ce développement fait suite au vote unanime du Comité consultatif des médicaments oncologiques de la FDA en avril 2024, qui a accepté le MRD comme critère clinique pour l'approbation accélérée de nouvelles thérapies pour le myélome multiple.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) gab die Annahme seiner Abstract-Einreichung durch die American Society of Clinical Oncology (ASCO) für die Jahrestagung 2025 bekannt. Das Abstract konzentriert sich auf die Analyse der Übereinstimmung zwischen Blut- und Knochenmarkproben unter Verwendung der TeloView® Minimal Residual Disease (MRD) Methodik.
Die laufenden MRD-Klinikstudien des Unternehmens mit der McGill-Universität/Jüdischen Allgemeinkrankenhaus zielen darauf ab, zwei prognostische Tests zu entwickeln: 1) Identifizierung und Quantifizierung von MRD-Zellen im Blut des Patienten nach einer Knochenmarktransplantation und 2) Profilierung isolierter zirkulierender MRD-Zellen mit der TeloView®-Technologie zur Bewertung der Aggressivität der Erkrankung. Beide Tests sind als Lösungen auf Basis von Flüssigbiopsien konzipiert.
Diese Entwicklung folgt der einstimmigen Abstimmung des Onkologischen Arzneimittelberatungs-Ausschusses der FDA im April 2024, die MRD als klinischen Endpunkt für die beschleunigte Genehmigung neuer Therapien bei multiplem Myelom akzeptiert hat.
- FDA's acceptance of MRD as clinical endpoint enables faster drug approvals, potentially accelerating market adoption
- Development of two novel liquid biopsy-based prognostic tests for multiple myeloma monitoring
- Recognition from prestigious ASCO conference validates technology significance
- Tests are still in clinical trial phase, not yet commercially available
- Validation data will only be presented as online publication, not as oral presentation
Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genomics' abstract submission regarding a concordance analysis between blood and marrow samples, using the TeloView® Minimal Residual Disease (MRD) methodology, as an online publication at the ASCO Annual Meeting.
MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals.
Telo's ongoing MRD clinical trials with McGill University/Jewish General Hospital have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include: i) identify and quantify the number of MRD cells circulating in the patient's blood post marrow transplantation; and ii) profile the isolated circulating MRD cells using Telo's proprietary technology TeloView®, to assess disease aggressiveness in each individual MRD cell. The two MRD tests are designed to be liquid biopsy-based, which is at the forefront of precision medicine.
ASCO's 2025 Annual Meeting will take place May 30 - June 3, 2025, in Chicago, Illinois. Founded in 1964, ASCO brings together more than 45,000 oncology professionals worldwide, dedicated to improving cancer care through research, education, and promotion of the highest quality patient care. ASCO is widely considered one of the most prestigious oncology research conferences of the year.
"We are really pleased to have our abstract accepted by ASCO, it indicates the novelty and importance of our TeloView® based MRD applications and the impact we hope to have on patients and physicians as they manage MM patients post-transplantation," said Sabine Mai, Telo's co-Founder.
About MRD Assessment
Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023).
About Multiple Myeloma
Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Guido Baechler
Executive Chairman
416-673-8487
info@telodx.com
MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248008
FAQ
What is the significance of ASCO accepting Telo Genomics' (TDSGF) MRD validation data?
How many prognostic tests is Telo Genomics (TDSGF) developing through its McGill University clinical trials?
What recent FDA decision supports Telo Genomics' (TDSGF) MRD testing development?
When and where will Telo Genomics (TDSGF) present its MRD validation data at ASCO 2025?
